SRZNW Projected Dividend Yield
Wt Exp 08/01/2032/Surrozen Inc ( NASDAQ : SRZNW )Surrozen, Inc. is a clinical-stage biotechnology company. Co. is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. Co. is developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen's SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. 21 YEAR PERFORMANCE RESULTS |
SRZNW Dividend History Detail SRZNW Dividend News SRZNW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |